Shelf life (days): 1460.0
Formulation: A crystalline solid
Formal Name: N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-[1,1'-biphenyl]-4-carboxamide, trifluoroacetate salt
Purity: ≥95%
Formula Markup: C26H26ClN5O / XCF3COOH
Formula Weight: 459.97044
Notes: BB-Cl-amidine is a pan inhibitor of peptidyl arginine deiminases (PADs) and a proteolysis-resistant derivative of Cl-amidine (Item No. 10599).{27726} It irreversibly inhibits PAD1-4 (kinact/KI = 16,100, 4,100, 6,800, and 13,300 M-1min-1, respectively).{18132,36047} BB-Cl-amidine (20 and 200 µM) inhibits the formation of neutrophil extracellular traps (NETs) induced by phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) without altering hydrogen peroxide (H2O2) production in bone marrow-derived neutrophils.{27726} It inhibits IFN-β production induced by the DNA virus herpes simplex virus 1 (HSV-1) but not the RNA virus Sendai virus in mouse bone marrow-derived macrophages (BMDMs) when used at a concentration of 1 µM.{65795} Ex vivo, BB-Cl-amidine (10 mg/kg) reduces BMDM IFN-β and TNF-α production induced by diABZI STING agonist-1 (Item No. 28054) in wild-type, Pad2-/-, and Pad4-/- mice. BB-Cl-amidine (20 mg/kg per day) increases survival, as well as reduces splenomegaly, myocarditis, and cardiac fibrosis in a Trex1D18N/D18N mouse model of Aicardi-Goutières syndrome (AGS).